Introduction {#tmi13290-sec-0005}
============

HIV is driving the TB epidemic in high HIV prevalence settings [1](#tmi13290-bib-0001){ref-type="ref"}, [2](#tmi13290-bib-0002){ref-type="ref"}, with sub‐Saharan Africa having the highest HIV prevalence and TB incidence globally [3](#tmi13290-bib-0003){ref-type="ref"}, [4](#tmi13290-bib-0004){ref-type="ref"}. TB has emerged as the main opportunistic infection in people living with HIV (PLHIV), with HIV co‐infection rates exceeding 50% in many southern African countries [4](#tmi13290-bib-0004){ref-type="ref"}.

Several patient‐level factors predict HIV‐associated TB including older age, male sex and advanced HIV disease [5](#tmi13290-bib-0005){ref-type="ref"}. Despite the protective effect of antiretroviral therapy (ART) against active TB disease across all baseline CD4 cell count strata, possibly stronger for lower CD4 count levels [6](#tmi13290-bib-0006){ref-type="ref"}, [7](#tmi13290-bib-0007){ref-type="ref"}, PLHIV receiving ART remain at higher risk of TB than the HIV‐negative population [7](#tmi13290-bib-0007){ref-type="ref"}, [8](#tmi13290-bib-0008){ref-type="ref"}, [9](#tmi13290-bib-0009){ref-type="ref"}. At the population‐level, ecological studies suggested a decline in annual TB notifications with expansion of HIV treatment eligibility criteria and increased ART coverage [2](#tmi13290-bib-0002){ref-type="ref"}, [10](#tmi13290-bib-0010){ref-type="ref"}, [11](#tmi13290-bib-0011){ref-type="ref"}, most pronounced in new and smear‐negative TB cases [2](#tmi13290-bib-0002){ref-type="ref"}, [10](#tmi13290-bib-0010){ref-type="ref"}, [12](#tmi13290-bib-0012){ref-type="ref"}. Although modelling studies overall support these findings, the long‐term impact of ART scale‐up on TB reduction remains inconclusive [13](#tmi13290-bib-0013){ref-type="ref"}, [14](#tmi13290-bib-0014){ref-type="ref"}, [15](#tmi13290-bib-0015){ref-type="ref"}. In some settings, the decline in TB occurred before or at the beginning of ART expansion [2](#tmi13290-bib-0002){ref-type="ref"}, [10](#tmi13290-bib-0010){ref-type="ref"}, suggesting other factors contributing to TB control [5](#tmi13290-bib-0005){ref-type="ref"}, [10](#tmi13290-bib-0010){ref-type="ref"}, [16](#tmi13290-bib-0016){ref-type="ref"}, [17](#tmi13290-bib-0017){ref-type="ref"}. For instance: (1) increased TB programme coverage, diagnosis and effective treatment is believed to reduce TB prevalence and mortality; (2) ART expansion is likely to drive the decline in incident TB in PLHIV; and (3) both interventions combined in high HIV‐TB prevalence settings may have a synergistic effect [13](#tmi13290-bib-0013){ref-type="ref"}. Other factors are level of care and HIV prevalence at district level [5](#tmi13290-bib-0005){ref-type="ref"}, [18](#tmi13290-bib-0018){ref-type="ref"}.

Eswatini (former Swaziland) -- the country with the highest HIV prevalence (32% in 18‐ to 49‐year‐olds) in the world [19](#tmi13290-bib-0019){ref-type="ref"} -- experienced significant changes in the TB epidemic. In 2012 it had the highest annual TB incidence (1350/100 000 population) globally and 77% of TB patients were HIV co‐infected [20](#tmi13290-bib-0020){ref-type="ref"}. Since then, estimated incidence rapidly declined to 398 cases per 100 000 population in 2016 [4](#tmi13290-bib-0004){ref-type="ref"}, coinciding with changes in TB programme interventions [17](#tmi13290-bib-0017){ref-type="ref"} and unprecedented ART expansion. This is the first study from Eswatini examining both patient‐ and population‐level predictors and trends of HIV‐associated TB during progressive expansion of HIV‐TB care over a period of 8 years.

Methods {#tmi13290-sec-0006}
=======

Context {#tmi13290-sec-0007}
-------

The predominantly rural Shiselweni region in southern Eswatini had a population of approximately 209 000 in 2009 [21](#tmi13290-bib-0021){ref-type="ref"}. The peak of the TB epidemic in Eswatini was during 2009--2010, and in 2009, the Shiselweni region had the highest reported case notification rate (1293/100 000 population) in the country (see Appendix [S1](#tmi13290-sup-0001){ref-type="supplementary-material"}, Figures [S1‐S2](#tmi13290-sup-0001){ref-type="supplementary-material"}) [22](#tmi13290-bib-0022){ref-type="ref"}. The Ministry of Health supported by Médecins Sans Frontières (MSF) provided free ambulatory HIV and TB care (diagnosis, treatment initiation and treatment follow‐up) at three secondary health facilities and integrated it into 22 nurse‐led mobile doctor‐supported primary care clinics from 2009 to 2010. A description of changes in TB programing can be found elsewhere [17](#tmi13290-bib-0017){ref-type="ref"}, [23](#tmi13290-bib-0023){ref-type="ref"}. In summary, the Stop‐TB strategy was adopted in 2009 and comprised intensified TB screening, introduction of infection control measures and provision of isoniazid preventive therapy (in 2012). TB diagnosis was based on sputum smear‐microscopy, which was increasingly replaced by Xpert MTB/RIF from late 2011. Due to high HIV co‐infection rates, empiric TB therapy was encouraged following World Health Organisation (WHO) recommendations [24](#tmi13290-bib-0024){ref-type="ref"}. HIV co‐infected TB patients were eligible for ART irrespective of CD4 cell count, and the ART eligibility threshold for non‐TB patients was expanded from 200 to 350 cells/mm^3^ in 2010 and to 500 cells/mm^3^ in 2015. One of the three health clusters introduced prompt ART initiation irrespective of immunologic criteria, in January 2013 under the prevention of mother‐to‐child transmission (PMTCT) option B+ approach [25](#tmi13290-bib-0025){ref-type="ref"}, [26](#tmi13290-bib-0026){ref-type="ref"} and in October 2014 for all PLHIV (the WHO treat‐all approach).

Study design, data management and definitions {#tmi13290-sec-0008}
---------------------------------------------

We analysed patient‐level (retrospective cohort analysis) and population‐level (ecological analysis) temporal trends and predictors of TB notifications in the Shiselweni region from January 2009 to December 2016. A TB notification case was defined as a patient starting treatment for drug‐sensitive or resistant TB. Patient‐level data were routinely abstracted from health facility records and entered into electronic TB treatment databases used for routine programme monitoring. Patients transferred in from another facility or outside the region were removed from analyses. Patients restarting TB therapy after treatment interruption or transitioning from first‐ to second‐line TB drug treatment (e.g. treatment failure) were counted once at the time of starting the first TB treatment course. The number of patients active on ART was obtained from the national electronic ART treatment database.

The electronic TB treatment register was maintained by MSF and the electronic ART database by the Ministry of Health with support for data entry by trained MSF data clerks at regional level. Data quality checks and data cleaning were routinely performed as well as data workshops addressing data completeness and reliability. Although these databases were not formally validated against other databases (e.g. laboratory data), the data obtained from the electronic TB database and from paper TB treatment registers were found to be consistent during data reviews.

Statistics {#tmi13290-sec-0009}
----------

### Cohort analysis {#tmi13290-sec-0010}

Baseline data were compared using the Pearson\'s chi‐squared test. Multiple imputation by chained equations was used to handle missing data (see Appendix [S2](#tmi13290-sup-0001){ref-type="supplementary-material"}) [27](#tmi13290-bib-0027){ref-type="ref"}. A multivariate logistic regression model with 10 imputed datasets was used to describe predictors of HIV‐associated TB. Variables for inclusion were determined a priori based on knowledge from previous studies.

### Ecological analysis {#tmi13290-sec-0011}

First, TB notification rates were calculated separately in each imputed dataset and then averaged across the 10 imputed datasets to create one dataset with complete observations to describe crude and standardised annual rates of TB notifications per 100 000 person‐years. Numerators of number of TB cases stratified by sex, age and HIV status were divided by the corresponding mid‐year projected regional population estimates (denominators) of the 2007 Eswatini population and housing census [21](#tmi13290-bib-0021){ref-type="ref"}, [28](#tmi13290-bib-0028){ref-type="ref"}. To obtain stratified denominators of PLHIV, sex‐ and age‐stratified population data were multiplied by the corresponding regional HIV prevalence estimates. Because regional stratified HIV prevalence estimates were not available from a single source, we used the 2011 Swaziland HIV Incidence Measurement Survey (SHIMS) estimates [19](#tmi13290-bib-0019){ref-type="ref"}, [29](#tmi13290-bib-0029){ref-type="ref"} for the 20‐ to 49‐year‐olds, the 2006--2007 Demographic and Health Survey (DHS) estimates [28](#tmi13290-bib-0028){ref-type="ref"} for the ≤14‐ and ≥50‐year‐olds, and averaged SHIMS and DHS prevalence estimates for the 15‐ to 19‐year‐olds. Finally, the stratified mid‐year numbers of patients active on ART were divided by the corresponding stratified population estimates of PLHIV to obtain sex‐ and age‐stratified ART coverage estimates.

Second, because the outcome was number of TB cases and data showed overdispersion, we built negative binomial regression models to obtain population‐level adjusted incidence risk ratios (aIRR). Model‐1 considered the entire study period adjusted for the population‐level covariates sex, age and HIV status. Model‐2 combined HIV status and ART status into one covariate with three categories (HIV‐negative case, PLHIV on ART, PLHIV without ART), but was restricted to the years from 2009 to 2014 as reliable stratified ART coverage estimates were not available for the time period thereafter.

Finally, we plotted trends in TB notifications and ART coverage between 2008 and 2016. To complement missing information, the national TB programme annual report [22](#tmi13290-bib-0022){ref-type="ref"} provided the 2008 regional TB notification estimate, and the first and second Swaziland HIV Incidence Measurement Surveys [19](#tmi13290-bib-0019){ref-type="ref"}, [29](#tmi13290-bib-0029){ref-type="ref"}, [30](#tmi13290-bib-0030){ref-type="ref"} provided the regional 2011 and regional 2016 ART coverage estimates overall and separately for men and women.

Analyses were performed with Stata/SE 14.1 (College Station, Texas, USA).

Ethics {#tmi13290-sec-0012}
------

This analysis was approved by the Eswatini National Health Research Review Board and the University of Cape Town Ethics committee. This research fulfilled the exemption criteria set by the MSF Ethics Review Board (ERB) for posteriori analyses of routinely collected clinical data and thus did not require MSF ERB review. It was conducted with permission from Micaela Serafini (Medical Director, Operational Centre Geneva, MSF).

Results {#tmi13290-sec-0013}
=======

Of 11 328 TB treatment notifications in Shiselweni, the annual number declined from 2800 to 566 between 2009 and 2016 and in all age groups irrespective of HIV status (Table [1](#tmi13290-tbl-0001){ref-type="table"}a, Figure [1](#tmi13290-fig-0001){ref-type="fig"}). From 2009 to 2010, most cases (96.4% and 70.8%) started TB treatment at secondary care facilities and approximately half of them at primary care clinics the years thereafter (see Appendix [S3](#tmi13290-sup-0001){ref-type="supplementary-material"}, Figure [S5](#tmi13290-sup-0001){ref-type="supplementary-material"}a). The proportion of patients with unknown HIV status decreased from 10.6% in 2009 to 1.4% in 2016 (Figure [S5](#tmi13290-sup-0001){ref-type="supplementary-material"}b).

###### 

Temporal trends in TB notifications, overall (a) and for HIV‐associated TB cases (b)

                                                        2009          2010          2011          2012            2013          2014          2015          2016          Total
  ----------------------------------------------------- ------------- ------------- ------------- --------------- ------------- ------------- ------------- ------------- -------------
  \(a\)                                                                                                                                                                   
  TB notifications, overall                             2800          2333          1745          1316            963           914           691           566           11 328
  Healthcare level                                                                                                                                                        
  Primary                                               101 (3.6)     681 (29.2)    921 (52.8)    669 (50.8)      485 (50.4)    462 (50.5)    354 (51.2)    296 (52.3)    3969 (35.0)
  Secondary                                             2699 (96.4)   1652 (70.8)   824 (47.2)    647 (49.2)      478 (49.6)    452 (49.5)    337 (48.8)    270 (47.7)    7359 (65.0)
  HIV status                                                                                                                                                              
  Negative                                              446 (15.9)    452 (19.4)    436 (25.0)    342 (26.0)      262 (27.2)    265 (29.0)    218 (31.5)    170 (30.0)    2591 (22.9)
  Positive                                              2056 (73.4)   1660 (71.2)   1235 (70.8)   945 (71.8)      690 (71.7)    643 (70.4)    466 (67.4)    388 (68.6)    8083 (71.4)
  Missing                                               298 (10.6)    221 (9.5)     74 (4.2)      29 (2.2)        11 (1.1)      6 (0.7)       7 (1.0)       8 (1.4)       654 (5.8)
  \(b\)                                                                                                                                                                   
  HIV‐associated TB notifications                       2056          1660          1235          945             690           643           466           388           8083
  Age, years (IQR) (n missing = 30)                     32 (26--40)   31 (24--41)   33 (26--42)   32.5 (26--42)   34 (28--43)   33 (28--40)   33 (28--41)   34 (28--40)   32 (26--41)
  Sex                                                                                                                                                                     
  Females                                               1130 (55.0)   915 (55.1)    645 (52.2)    474 (50.2)      323 (46.8)    300 (46.7)    222 (47.6)    175 (45.1)    4184 (51.8)
  Males                                                 926 (45.0)    745 (44.9)    590 (47.8)    471 (49.8)      367 (53.2)    343 (53.3)    244 (52.4)    213 (54.9)    3899 (48.2)
  Male/female ratio                                     0.82          0.81          0.91          0.99            1.14          1.14          1.10          1.22          0.93
  TB site                                                                                                                                                                 
  Pulmonary                                             1745 (84.9)   1459 (87.9)   1098 (88.9)   824 (87.2)      578 (83.8)    521 (81.0)    410 (88.0)    334 (86.1)    6969 (86.2)
  Extra‐pulmonary                                       303 (14.7)    194 (11.7)    134 (10.9)    119 (12.6)      106 (15.4)    120 (18.7)    55 (11.8)     53 (13.7)     1084 (13.4)
  Missing                                               8 (0.4)       7 (0.4)       3 (0.2)       2 (0.2)         6 (0.9)       2 (0.3)       1 (0.2)       1 (0.3)       30 (0.4)
  TB classification                                                                                                                                                       
  New case                                              1709 (83.1)   1377 (83.0)   1076 (87.1)   861 (91.1)      626 (90.7)    577 (89.7)    407 (87.3)    347 (89.4)    6980 (86.4)
  Recurrent case                                        334 (16.2)    275 (16.6)    151 (12.2)    80 (8.5)        64 (9.3)      63 (9.8)      57 (12.2)     41 (10.6)     1065 (13.2)
  Missing                                               13 (0.6)      8 (0.5)       8 (0.6)       4 (0.4)         0 (0.0)       3 (0.5)       2 (0.4)       0 (0.0)       38 (0.5)
  TB treatment type                                                                                                                                                       
  First line                                            2043 (99.4)   1641 (98.9)   1201 (97.2)   890 (94.2)      650 (94.2)    601 (93.5)    420 (90.1)    358 (92.3)    7804 (96.5)
  Second line[\*](#tmi13290-note-0002){ref-type="fn"}   13 (0.6)      19 (1.1)      34 (2.8)      55 (5.8)        40 (5.8)      42 (6.5)      46 (9.9)      30 (7.7)      279 (3.5)
  Bacteriologic status                                                                                                                                                    
  Positive                                              720 (35.0)    475 (28.6)    385 (31.2)    449 (47.5)      413 (59.9)    407 (63.3)    368 (79.0)    317 (81.7)    3534 (43.7)
  Negative                                              1033 (50.2)   753 (45.4)    571 (46.2)    355 (37.6)      176 (25.5)    125 (19.4)    56 (12.0)     47 (12.1)     3116 (38.6)
  Missing                                               303 (14.7)    432 (26.0)    279 (22.6)    141 (14.9)      101 (14.6)    111 (17.3)    42 (9.0)      24 (6.2)      1433 (17.7)
  Time of HIV diagnosis, days                                                                                                                                             
  ≥91 days before TB treatment                          651 (31.7)    523 (31.5)    339 (27.4)    322 (34.1)      244 (35.4)    258 (40.1)    198 (42.5)    170 (43.8)    2705 (33.5)
  90--1 days before TB treatment                        827 (40.2)    591 (35.6)    489 (39.6)    369 (39.0)      291 (42.2)    257 (40.0)    175 (37.6)    139 (35.8)    3138 (38.8)
  During TB treatment                                   535 (26.0)    462 (27.8)    336 (27.2)    207 (21.9)      115 (16.7)    100 (15.6)    60 (12.9)     59 (15.2)     1874 (23.2)
  Missing[†](#tmi13290-note-0003){ref-type="fn"}        43 (2.1)      84 (5.1)      71 (5.7)      47 (5.0)        40 (5.8)      28 (4.4)      33 (7.1)      20 (5.2)      366 (4.5)
  Time of ART initiation, days                                                                                                                                            
  ≥91 days before TB treatment                          277 (13.5)    268 (16.1)    203 (16.4)    195 (20.6)      173 (25.1)    166 (25.8)    147 (31.5)    138 (35.6)    1567 (19.4)
  90--1 days before TB treatment                        236 (11.5)    160 (9.6)     167 (13.5)    124 (13.1)      119 (17.2)    100 (15.6)    60 (12.9)     63 (16.2)     1029 (12.7)
  During TB treatment                                   330 (16.1)    470 (28.3)    484 (39.2)    450 (47.6)      264 (38.3)    285 (44.3)    186 (39.9)    149 (38.4)    2618 (32.4)
  Missing                                               1213 (59.0)   762 (45.9)    381 (30.9)    176 (18.6)      134 (19.4)    92 (14.3)     73 (15.7)     38 (9.8)      2869 (35.5)
  Time of cotrimoxazole initiation, days                                                                                                                                  
  ≥91 days before TB treatment                          244 (11.9)    225 (13.6)    166 (13.4)    198 (21.0)      163 (23.6)    179 (27.8)    122 (26.2)    135 (34.8)    1432 (17.7)
  90--1 days before TB treatment                        350 (17.0)    293 (17.7)    301 (24.4)    276 (29.2)      245 (35.5)    215 (33.4)    136 (29.2)    125 (32.2)    1941 (24.0)
  During TB treatment                                   1224 (59.5)   837 (50.4)    525 (42.5)    277 (29.3)      146 (21.2)    135 (21.0)    93 (20.0)     85 (21.9)     3322 (41.1)
  Missing                                               238 (11.6)    305 (18.4)    243 (19.7)    194 (20.5)      136 (19.7)    114 (17.7)    115 (24.7)    43 (11.1)     1388 (17.2)

ART, antiretroviral therapy; IQR, interquartile range.

Second line TB treatment cases were patients who received a treatment regimen for mono‐resistance, poly‐resistance, multidrug resistance or extensive drug resistance TB.

These patients had a confirmed HIV‐positive status but the date of diagnosis was unknown.
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Trends in HIV‐associated TB notifications (cohort level) {#tmi13290-sec-0014}
--------------------------------------------------------

Of 8083 HIV co‐infected TB cases, the annual number declined from 2056 to 388 between 2009 and 2016 (Table [1](#tmi13290-tbl-0001){ref-type="table"}b, Figure [1](#tmi13290-fig-0001){ref-type="fig"}). The median age was 32 (interquartile range \[IQR\] 26--41) years, 86.2% had pulmonary TB, and 86.4% were new treatment cases without significant variations over time. The male‐to‐female ratio increased from 0.82 to 1.22 between 2008 and 2016, corresponding to 45.0% and 54.9% males, respectively. During the phase‐out of smear‐microscopy testing and phase‐in of Xpert testing in 2012 (see Appendix [S3](#tmi13290-sup-0001){ref-type="supplementary-material"}, Figure [S6](#tmi13290-sup-0001){ref-type="supplementary-material"}), bacteriologically confirmed TB increased from 35.0% in 2009 to 81.7% in 2016 while proportionally fewer had missing bacteriologic (14.7% vs. 6.2) status, respectively (Figure [S5](#tmi13290-sup-0001){ref-type="supplementary-material"}c). In 2009, 0.6% of patients started a second‐line TB drug treatment regimen compared with 7.7% in 2016 (Figure [S5](#tmi13290-sup-0001){ref-type="supplementary-material"}d). The proportion of patients diagnosed as HIV‐positive ≥91 days before starting TB treatment increased from 31.7% to 43.8% between 2009 and 2016. Regarding the timing of cotrimoxazole prophylaxis and ART initiation in relation to TB treatment and considering the same time period, the proportion of patients receiving cotrimoxazole prophylaxis ≥91 days before starting TB treatment increased from 11.9% to 34.8%, and the proportion of patients receiving ART before TB treatment increased from 13.5% to 35.6%, respectively (Figure [S5](#tmi13290-sup-0001){ref-type="supplementary-material"}e,f). Of note, 59.0% of patients had missing ART status in 2009 vs. 9.8% in 2016.

Patient‐level predictors of HIV‐associated TB {#tmi13290-sec-0015}
---------------------------------------------

All TB notification data (*n* = 11 328; 10 imputed datasets) were used in multivariate logistic regression analysis (Table [2](#tmi13290-tbl-0002){ref-type="table"}). The multiple imputation diagnostic was satisfied (see Appendix [S2](#tmi13290-sup-0001){ref-type="supplementary-material"}, Figure [S3--S4](#tmi13290-sup-0001){ref-type="supplementary-material"}). The probability of being an HIV‐positive TB treatment case fell in all years from 2011 (adjusted odds ratio \[aOR\] 0.69, 95% confidence interval \[CI\]: 0.58--0.83) to 2016 (aOR 0.54, 0.43--0.69) (vs. 2009), in the age groups ≤29 and ≥40 years old (vs. 35--39 years) and in males (aOR 0.65, 0.59--0.72). The probability was higher for secondary healthcare level (aOR 1.18, 1.06--1.33), recurrent TB (aOR 1.40, 1.19--1.65) and negative (aOR 1.31, 1.15--1.49) or missing (aOR 1.30, 1.11--1.53) bacteriologic status. No differences were detected for TB site and treatment regimen.

###### 

Baseline characteristics and uni‐ and multivariate associations with HIV among all patients with TB

                                                                        Baseline characteristics of TB cases (n = 10 674)[†](#tmi13290-note-0006){ref-type="fn"}   Predictors of HIV‐associated TB (n = 11 328)[§](#tmi13290-note-0008){ref-type="fn"}                                          
  --------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------- --------- ------ -------------- ------ --------------
  Total number (missing = 654)[†](#tmi13290-note-0006){ref-type="fn"}   2591                                                                                       8083                                                                                                                          
  Calendar year                                                                                                                                                                                                                                                                                 
  2009                                                                  446 (17.2)                                                                                 2056 (25.4)                                                                           \<0.001   1                     1       
  2010                                                                  452 (17.4)                                                                                 1660 (20.5)                                                                                     0.82   (0.70--0.94)   0.92   (0.78--1.09)
  2011                                                                  436 (16.8)                                                                                 1235 (15.3)                                                                                     0.64   (0.55--0.74)   0.69   (0.58--0.83)
  2012                                                                  342 (13.2)                                                                                 945 (11.7)                                                                                      0.62   (0.52--0.72)   0.71   (0.59--0.86)
  2013                                                                  262 (10.1)                                                                                 690 (8.5)                                                                                       0.60   (0.50--0.72)   0.70   (0.57--0.86)
  2014                                                                  265 (10.2)                                                                                 643 (8.0)                                                                                       0.55   (0.46--0.66)   0.53   (0.43--0.65)
  2015                                                                  218 (8.4)                                                                                  466 (5.8)                                                                                       0.49   (0.40--0.59)   0.53   (0.42--0.66)
  2016                                                                  170 (6.6)                                                                                  388 (4.8)                                                                                       0.52   (0.43--0.64)   0.54   (0.43--0.69)
  Healthcare level                                                                                                                                                                                                                                                                              
  Primary                                                               1148 (44.3)                                                                                2698 (33.4)                                                                           \<0.001   1                     1       
  Secondary                                                             1443 (55.7)                                                                                5385 (66.6)                                                                                     1.57   (1.43--1.71)   1.18   (1.06--1.33)
  Sex                                                                                                                                                                                                                                                                                           
  Females                                                               1060 (40.9)                                                                                4184 (51.8)                                                                           \<0.001   1                     1       
  Males                                                                 1531 (59.1)                                                                                3899 (48.2)                                                                                     0.65   (0.60--0.71)   0.65   (0.59--0.72)
  Age, years (missing = 30)                                                                                                                                                                                                                                                                     
  0--4                                                                  260 (3.2)                                                                                  481 (4.5)                                                                             \<0.001   0.11   (0.08--0.14)   0.08   (0.06--0.11)
  5--9                                                                  226 (2.8)                                                                                  327 (3.1)                                                                                       0.20   (0.14--0.27)   0.16   (0.11--0.22)
  10--14                                                                213 (2.6)                                                                                  305 (2.9)                                                                                       0.21   (0.15--0.28)   0.17   (0.12--0.23)
  15--19                                                                173 (2.1)                                                                                  407 (3.8)                                                                                       0.07   (0.05--0.09)   0.06   (0.05--0.08)
  20--24                                                                720 (8.9)                                                                                  1022 (9.6)                                                                                      0.21   (0.17--0.27)   0.19   (0.15--0.24)
  25--29                                                                1460 (18.1)                                                                                1701 (16.0)                                                                                     0.54   (0.42--0.69)   0.49   (0.38--0.63)
  30--34                                                                1538 (19.1)                                                                                1696 (16.0)                                                                                     0.86   (0.66--1.12)   0.85   (0.65--1.11)
  35--39                                                                1166 (14.5)                                                                                1268 (11.9)                                                                                     1                     1       
  40--45                                                                771 (9.6)                                                                                  887 (8.3)                                                                                       0.59   (0.45--0.78)   0.56   (0.43--0.75)
  45--49                                                                512 (6.4)                                                                                  629 (5.9)                                                                                       0.39   (0.30--0.52)   0.38   (0.29--0.51)
  50--54                                                                385 (4.8)                                                                                  517 (4.9)                                                                                       0.26   (0.20--0.35)   0.26   (0.20--0.35)
  55--59                                                                251 (3.1)                                                                                  398 (3.7)                                                                                       0.15   (0.12--0.21)   0.15   (0.11--0.21)
  ≥60                                                                   378 (4.7)                                                                                  986 (9.3)                                                                                       0.06   (0.04--0.07)   0.05   (0.04--0.06)
  TB site (missing = 30)                                                                                                                                                                                                                                                                        
  Pulmonary                                                             2285 (88.4)                                                                                6969 (86.5)                                                                           0.013     1                     1       
  Extra‐pulmonary[\*](#tmi13290-note-0005){ref-type="fn"}               299 (11.6)                                                                                 1084 (13.5)                                                                                     1.19   (1.04--1.36)   1.06   (0.91--1.24)
  TB classification (missing = 38)                                                                                                                                                                                                                                                              
  New case                                                              2345 (90.9)                                                                                6980 (86.8)                                                                           \<0.001   1                     1       
  Recurrent case                                                        234 (9.1)                                                                                  1065 (13.2)                                                                                     1.50   (1.30--1.74)   1.40   (1.19--1.65)
  Bacteriologic status                                                                                                                                                                                                                                                                          
  Positive                                                              1197 (46.2)                                                                                3534 (43.7)                                                                           \<0.001   1                     1       
  Negative                                                              840 (32.4)                                                                                 3116 (38.6)                                                                                     1.25   (1.13--1.39)   1.31   (1.15--1.49)
  Missing                                                               554 (21.4)                                                                                 1433 (17.7)                                                                                     0.85   (0.75--0.95)   1.30   (1.11--1.53)
  TB treatment type                                                                                                                                                                                                                                                                             
  First line                                                            2516 (97.1)                                                                                7804 (96.5)                                                                           0.168     1                     1       
  Second line[‡](#tmi13290-note-0007){ref-type="fn"}                    75 (2.9)                                                                                   279 (3.5)                                                                                       1.21   (0.93--1.56)   1.16   (0.86--1.56)

OR, odds ratio from univariate analysis; aOR, adjusted odds ratio from multivariate analysis; CI, confidence interval.

Patients diagnosed with both pulmonary and extra‐pulmonary TB are counted under extra‐pulmonary TB.

Among all patients (*n* = 11 328), 654 (5.8%) had missing HIV status and were not included in description of baseline characteristics.

Second line TB treatment cases were patients who received a treatment regimen for mono‐resistance, poly‐resistance, multidrug resistance or extensive drug resistance TB.

Missing values of HIV status, age, TB site and TB classification were imputed into 10 datasets. Thus all observations (*n* = 11 328) were used in multivariate logistic regression analysis.

John Wiley & Sons, Ltd

Population‐level trends in TB notification {#tmi13290-sec-0016}
------------------------------------------

Population‐level adjusted TB notification rates per 100 000 person‐years are presented in Appendix [S3](#tmi13290-sup-0001){ref-type="supplementary-material"}, Table [S1--S2](#tmi13290-sup-0001){ref-type="supplementary-material"}. The overall TB notification rate decreased fivefold between 2009 and 2016, from 1341 to 269 per 100 000 person‐years (Figure [1](#tmi13290-fig-0001){ref-type="fig"}a,b). The decline was more pronounced in females (sixfold) than males (4.2‐fold) and more pronounced in PLHIV (sixfold) than in the HIV‐negative population (threefold). The decline was 7.2‐ and 4.9‐fold for HIV‐positive females and males vs. 3.6‐ and 2.7‐fold for HIV‐negative females and males, respectively (Figure [1](#tmi13290-fig-0001){ref-type="fig"}c,d).

Figure [2](#tmi13290-fig-0002){ref-type="fig"}a--d shows that TB notifications declined in all age groups and irrespective of HIV status. TB notifications were highest in middle‐aged females, while they also remained high for older males. For the HIV‐negative population, TB notifications steadily increased with age while a U‐shaped pattern was seen for HIV‐positive cases in the early years, with higher notification rates in the younger and older age groups. Although PLHIV sustained higher notification rates for all ages, the age pattern of the combined year 2015--2016 was similar to the HIV‐negative population with notification rates steadily increasing with age.

![Age‐stratified temporal trends in TB notifications (absolute numbers vs. rates) for HIV‐positive and HIV‐negative cases. \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](TMI-24-1114-g002){#tmi13290-fig-0002}

Population‐level predictors of TB {#tmi13290-sec-0017}
---------------------------------

In both models, men had an approximately 1.8‐fold increased risk of TB. Compared with 35‐ to 39‐year‐olds, younger age (≤19 years) decreased the risk of TB while older age (≥55 years) increased it. In Model‐1 (see Appendix [S3](#tmi13290-sup-0001){ref-type="supplementary-material"}, Table [S3](#tmi13290-sup-0001){ref-type="supplementary-material"}), an HIV‐positive status (irrespective of ART) increased the risk of TB by 19.5 times (adjusted incidence risk ratio \[aIRR\] 19.47, 95% CI: 14.89--25.46). In Model‐2 (see Appendix [S3](#tmi13290-sup-0001){ref-type="supplementary-material"}, Table [S4](#tmi13290-sup-0001){ref-type="supplementary-material"}), the risk was 5.3 times higher in PLHIV on ART (aIRR 5.30, 3.94--7.12) and 12.3 times higher in PLHIV not on ART (aIRR 12.26, 9.07--16.56).

In both models, calendar year interacted with HIV/ART status. Comparing 2016 with 2009 in Model‐1, the effect of calendar year on declining TB was higher in PLHIV (aIRR 0.13, 95% CI: 0.10--0.17) than in HIV‐negative people (aIRR 0.32, 0.24--0.44) (Figure [3](#tmi13290-fig-0003){ref-type="fig"}a). In Model‐2, the year 2016 (vs. 2009) had the most pronounced protective effect for PLHIV not on ART (aIRR 0.15, 0.10--0.20), followed by HIV‐negative people (aIRR 0.27, 0.20--0.37) and by PLHIV on ART (aIRR 0.50, 0.36--0.70), while the effect of calendar year was similar for the years 2010 to 2012 (Figure [3](#tmi13290-fig-0003){ref-type="fig"}b).

![The effect of calendar year on TB notifications in Model‐1 (a) and Model‐2 (b). aIRR, adjusted incidence risk ratio. \*Model‐1 considered the entire study period adjusted for the population‐level covariates sex, age and HIV status. \*\*Model‐2 combined HIV status and ART status into one covariate with three categories (HIV‐negative case, PLHIV on ART, PLHIV without ART), but was restricted to the years from 2009 to 2014 as reliable stratified ART coverage estimates were not available for the time period thereafter. \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](TMI-24-1114-g003){#tmi13290-fig-0003}

ART coverage trends and declining TB from 2008 to 2016 {#tmi13290-sec-0018}
------------------------------------------------------

The TB notification rate was 1078 cases per 100 000 population in 2008 [22](#tmi13290-bib-0022){ref-type="ref"}, and the peak was in 2009 (Figure [4](#tmi13290-fig-0004){ref-type="fig"}). ART coverage increased from 22.0% (*n* = 7766) in 2009, to 55.7% (*n* = 20 139) in 2014 (study data), and to 82.7% in 2016 [30](#tmi13290-bib-0030){ref-type="ref"}. ART coverage was similar for both gender in 2011 (men: 36.7%; women: 35.6%) [19](#tmi13290-bib-0019){ref-type="ref"}, [29](#tmi13290-bib-0029){ref-type="ref"}, but point estimates tended to be higher for women in 2016 (men: 79.1%; women: 84.1%) [30](#tmi13290-bib-0030){ref-type="ref"}. During the first year of TB decline in 2010, ART coverage was between 22.0% and 29.9%. When the pace of TB decline reduced in 2014, ART coverage was between 50.8% and 55.7%.

![Temporal trends in TB notifications and ART coverage from 2008 to 2016. This graph combines estimates from the study (blue and red lines) and data points obtained from the annual TB report for TB notifications in 2008 \[22\] and from the Swaziland HIV Incidence Measurement Surveys for ART coverage in 2011 \[19,29\] and 2016 \[30\]. Blue line: ART coverage for all age groups combined. Red line: TB notification rates for all age groups combined irrespective of HIV status. DP‐1, data point 1: TB notification per 100 000 population in 2008 \[22\]. DP‐2, data point 2: ART coverage in ≥18 to 49‐year‐olds in 2011 \[19,29\]. DP‐3, data point 3: ART coverage in ≥15‐year‐olds in 2016 \[30\]. \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](TMI-24-1114-g004){#tmi13290-fig-0004}

Discussion {#tmi13290-sec-0019}
==========

We describe patient‐ and population‐level predictors and trends of HIV‐associated TB from a high HIV‐TB prevalence setting in rural Eswatini. The absolute numbers of TB cases as well as the incidence decreased rapidly over a period of 8 years for both sexes and all age groups and was most pronounced in PLHIV, coinciding with an almost fourfold increase in ART coverage, but was also seen in HIV‐uninfected patients.

Findings in context {#tmi13290-sec-0020}
-------------------

TB notifications reached unprecedented levels in 2009, with similar trends seen in the other three regions of Eswatini [22](#tmi13290-bib-0022){ref-type="ref"}. When the trend reversed in 2010, ART coverage was between 22% and 30% vs. 15--20% and 30--40% in peri‐urban and urban high HIV prevalence settings in South Africa [16](#tmi13290-bib-0016){ref-type="ref"}, [18](#tmi13290-bib-0018){ref-type="ref"}. When the pace of decline slowed down in 2014, ART coverage was between 51% and 56%. A modelling study suggested that ART programmes are needed to sustain high levels of ART adherence and good immunologic response to avert TB rebound [14](#tmi13290-bib-0014){ref-type="ref"}. TB rebound was not detected in this setting, with viral load suppression rates in ART patients being ≥84% [26](#tmi13290-bib-0026){ref-type="ref"}, [31](#tmi13290-bib-0031){ref-type="ref"}.

Calendar year interacted with HIV and ART status. The protective effect of the most recent calendar year (vs. the baseline year) was most pronounced for PLHIV without ART, followed by HIV‐negative people and PLHIV on ART. First, this was possibly due to different patterns in population‐level trends of median CD4 cell counts. Previous treatment guidelines restricted ART initiation to patients with low CD4 cell counts [32](#tmi13290-bib-0032){ref-type="ref"}, [33](#tmi13290-bib-0033){ref-type="ref"}, possibly resulting in a higher population‐level median CD4 count for PLHIV not on ART. An increased risk of TB has been documented for PLHIV with low CD4 cell counts and during the first 4 months after ART initiation (unmasking of subclinical TB) [34](#tmi13290-bib-0034){ref-type="ref"}, [35](#tmi13290-bib-0035){ref-type="ref"}. In addition, ART patients may have spent a long time at low CD4 cell counts [34](#tmi13290-bib-0034){ref-type="ref"} and the effect of immune dysfunction persists despite treatment [7](#tmi13290-bib-0007){ref-type="ref"}. In this setting, the overall infectious pool was largely reduced by fewer PLHIV being co‐infected with TB, which is expected to reduce infectious contacts for the HIV‐negative population, explaining the decline in HIV‐negative TB. Second, the temporal decline in TB may be due to the synergistic effect of TB and HIV programmatic achievements [13](#tmi13290-bib-0013){ref-type="ref"} possibly affecting the HIV‐negative population and PLHIV differently. For instance, national TB data suggested increased ART initiation and cotrimoxazole prophylaxis and reduced adverse TB treatment outcomes in co‐infected TB patients [23](#tmi13290-bib-0023){ref-type="ref"}. The introduction of isoniazid preventive therapy for PLHIV in 2012 may also have contributed to a decline in TB cases in PLHIV in later years, although its predicted population‐level impact in hyperendemic settings is likely smaller than in intermediate TB incidence contexts [36](#tmi13290-bib-0036){ref-type="ref"}, [37](#tmi13290-bib-0037){ref-type="ref"}. In addition, a recent modelling study concluded that ART expansion and high ART coverage are the most important factor in southern and eastern Africa to decrease TB in the HIV‐positive population and to a lesser extent in the HIV‐negative population, while improvements in TB case detection, TB treatment success and isoniazid preventive therapy play no or only a minor role [38](#tmi13290-bib-0038){ref-type="ref"}. In fact, the decline in active TB disease coincided with an unprecedented population‐level impact of the HIV programme in the study area. In 2016, 91.3% of PLHIV were aware of their HIV‐positive status, 82.7% of PLHIV accessed ART and 79.1% of PLHIV were virally suppressed [30](#tmi13290-bib-0030){ref-type="ref"}.

Although PLHIV sustained an increased risk of active TB disease in this study, TB as an entry point into HIV care became less significant in recent years. The number of HIV co‐infected TB cases decreased and proportionally more PLHIV already knew their HIV‐positive status, received cotrimoxazole and were on ART for more than 3 months when starting TB therapy.

This study suggests that national guidelines for the diagnosis and management of TB in HIV co‐infected patients were translated into routine practice. HIV‐associated TB was more likely in bacteriologically negative, extra‐pulmonary and recurrent TB cases. First, patients with advanced HIV disease are more likely to have atypical disease presentation, recurrent TB episodes and bacteriologically negative TB [7](#tmi13290-bib-0007){ref-type="ref"}, [39](#tmi13290-bib-0039){ref-type="ref"}, [40](#tmi13290-bib-0040){ref-type="ref"}, [41](#tmi13290-bib-0041){ref-type="ref"}. To avoid underdiagnoses and treatment delays for smear‐negative TB cases, clinicians followed diagnostic algorithms designed for resource‐poor, high HIV‐TB prevalence settings, allowing ambulatory empiric therapy based on clinical suspicion [24](#tmi13290-bib-0024){ref-type="ref"}. Second, the proportion of patients with missing or negative bacteriologic status decreased over time. This was likely due to the replacement of smear‐microscopy with the Xpert MTB/RIF assay, which is a more sensitive tool in detecting TB, specifically among HIV co‐infected patients [42](#tmi13290-bib-0042){ref-type="ref"}. Yet despite Xpert, empiric therapy continued to play a role (18% in 2016), likely due to extra‐pulmonary TB and programmatic factors, as was also reported from other settings [43](#tmi13290-bib-0043){ref-type="ref"}, [44](#tmi13290-bib-0044){ref-type="ref"}, [45](#tmi13290-bib-0045){ref-type="ref"}. Third, diagnosis in secondary‐level health care was also associated with HIV‐associated TB, probably because sicker patients with HIV co‐infection were more likely to access and health workers to refer complicated cases (e.g. bacteriologically negative TB) to higher healthcare levels.

We noticed sex disparities. Despite an increase in the male‐to‐female ratio to 1.2, it remained significantly lower than the ratio of 1.7 globally [46](#tmi13290-bib-0046){ref-type="ref"}. In addition, the probability of HIV‐associated TB was reduced in men at patient‐level but increased at population‐level. Sex disparities may be caused by an interplay of sex‐specific differences in HIV burden, access to TB services and biologic factors [47](#tmi13290-bib-0047){ref-type="ref"}, [48](#tmi13290-bib-0048){ref-type="ref"}. For instance, while higher HIV prevalence in women [19](#tmi13290-bib-0019){ref-type="ref"}, [30](#tmi13290-bib-0030){ref-type="ref"} likely disproportionally increased their vulnerability to TB disease at population‐level prior ART expansion, women appeared to benefit more from HIV service expansion through earlier initiation of ART, better treatment outcomes and higher ART coverage [30](#tmi13290-bib-0030){ref-type="ref"}, [49](#tmi13290-bib-0049){ref-type="ref"}. A similar trend was reported from neighbouring KwaZulu‐Natal (South Africa) where women had a more pronounced decline in HIV/TB related deaths during the rapid roll out of ART [50](#tmi13290-bib-0050){ref-type="ref"}. Notably, during our entire study period the male‐to‐female ratio remained lower than in low HIV prevalence settings, indicating persistent high risk of TB disease in HIV‐positive women despite high ART coverage.

Finally, the mid‐year ages (35--39 years old) were also predictive of HIV‐associated TB. This all reflects the state of the HIV epidemic, with females and middle‐aged adults having the highest HIV burden [19](#tmi13290-bib-0019){ref-type="ref"}, [29](#tmi13290-bib-0029){ref-type="ref"}.

Considerations for the future {#tmi13290-sec-0021}
-----------------------------

HIV‐associated TB and the slow global decline of TB may jeopardise achievement of the ambitious targets of the End TB strategy [46](#tmi13290-bib-0046){ref-type="ref"}, [51](#tmi13290-bib-0051){ref-type="ref"}. HIV and TB programmes should continue to target populations at increased risk of TB disease and those with the most unfavourable treatment outcomes (e.g. PLHIV, children [52](#tmi13290-bib-0052){ref-type="ref"}, [53](#tmi13290-bib-0053){ref-type="ref"}, [54](#tmi13290-bib-0054){ref-type="ref"}, [55](#tmi13290-bib-0055){ref-type="ref"}). Despite this unprecedented success, the estimated TB incidence in Eswatini remained one of the highest in the world in 2016 [4](#tmi13290-bib-0004){ref-type="ref"}. In this context, the impact of further ART expansion on the TB burden remains uncertain, given a slowing of the downward trends in TB notifications at the already high ART coverage achieved. There is the need of continued focus on health system factors. We believe that decentralisation of HIV and TB services were most important to improve timely access to diagnosis and treatment in our setting. Quality of care also likely improved over time as suggested by our data (e.g. increase in bacteriologically confirmed TB cases, improved documentation) as well as TB treatment success rates [56](#tmi13290-bib-0056){ref-type="ref"}. Although ART will likely remain the corner stone for controlling the TB epidemic in high HIV prevalence settings [38](#tmi13290-bib-0038){ref-type="ref"}, combining a wide range of recommended strategies and interventions into routine practice appears crucial [51](#tmi13290-bib-0051){ref-type="ref"}, [57](#tmi13290-bib-0057){ref-type="ref"}: (i) decreasing the pool of transmittable TB through earlier detection by increased index case tracing and the use of sensitive (e.g. Xpert MTB/RIF Ultra) and point‐of‐care tests (urine lipoarabinomannan assay) [58](#tmi13290-bib-0058){ref-type="ref"}, [59](#tmi13290-bib-0059){ref-type="ref"}, [60](#tmi13290-bib-0060){ref-type="ref"}, [61](#tmi13290-bib-0061){ref-type="ref"}; (ii) reducing delays between TB detection and treatment by strengthened decentralised and integrated HIV‐TB service [57](#tmi13290-bib-0057){ref-type="ref"}, [62](#tmi13290-bib-0062){ref-type="ref"}; (iii) improving TB treatment outcomes with more effective and more tolerable TB treatment regimens; (iv) combining TB and HIV interventions and ART initiation at high CD4 cell counts [34](#tmi13290-bib-0034){ref-type="ref"}; and (v) provision of extended isoniazid or other TB preventive treatment for PLHIV.

Limitations and strengths {#tmi13290-sec-0022}
-------------------------

First, this study likely underestimated TB incidence because TB treatment case notifications do not account for undiagnosed TB [63](#tmi13290-bib-0063){ref-type="ref"} or for pre‐treatment loss between diagnosis and treatment initiation, which can be as high as 38% [64](#tmi13290-bib-0064){ref-type="ref"}. For instance, our electronic TB register was not linked to the presumptive TB register and the laboratory database, thus possibly missing Xpert and smear positive TB cases that have never been notified about their disease or being lost administratively before registration as a TB treatment case. Suboptimal completeness and reliability of routine TB surveillance data have also been reported from South Africa [65](#tmi13290-bib-0065){ref-type="ref"}. On the other hand, the introduction of Xpert may have increased TB detection in culture‐positive cases [66](#tmi13290-bib-0066){ref-type="ref"}, and some patients receiving empiric treatment may not be real TB cases [67](#tmi13290-bib-0067){ref-type="ref"}, possibly increasing estimates. Second, the ecological study design cannot assess a possible causal relationship between ART scale‐up and population‐level decline in TB cases. We could also not account for other external factors such as changes in HIV‐TB programming and migration patterns. Specifically we could not adjust for the expansion of isoniazid preventive therapy since 2012 as data were incomplete and inconsistent. Not adjusting for it, however, could result in overestimation of the population‐level effect of ART on TB notifications in PLHIV. Finally, this analysis was restricted to the Shiselweni region of Eswatini as patient‐level data from other regions were not available.

A strength of this study was the use of stratified patient‐level data over 8 years in a predominantly rural setting. Previous studies were conducted in urban settings [5](#tmi13290-bib-0005){ref-type="ref"}, [16](#tmi13290-bib-0016){ref-type="ref"}, [18](#tmi13290-bib-0018){ref-type="ref"} and used aggregated national level data [2](#tmi13290-bib-0002){ref-type="ref"}, [10](#tmi13290-bib-0010){ref-type="ref"}, [17](#tmi13290-bib-0017){ref-type="ref"}. Few studies have reported from rural settings [12](#tmi13290-bib-0012){ref-type="ref"}, and some of those using patient‐level data [5](#tmi13290-bib-0005){ref-type="ref"}, [16](#tmi13290-bib-0016){ref-type="ref"}, [18](#tmi13290-bib-0018){ref-type="ref"} reported from the years before ART expansion beyond the 350 cells/mm^3^ threshold [16](#tmi13290-bib-0016){ref-type="ref"}. Finally, we analysed both patient‐ and population‐level trends and predictors of active TB disease and could provide a comprehensive picture of trends in the TB epidemic in this resource‐poor setting.

Conclusions {#tmi13290-sec-0023}
===========

This rural, high HIV‐TB prevalence setting experienced a rapid decline in TB notifications that was most pronounced in the HIV‐infected population but also saw declines in the HIV‐uninfected population. ART expansion and changes in HIV‐TB programming were likely important contributing factors. However, the TB epidemic is far from over, calling for concerted international efforts to continue ART expansion and to accelerate implementation of improved TB prevention and treatment interventions.
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